Video

Celestia S. Higano on Sexual Health and Pelvic Floor Physiotherapy

Author(s):

Celestia S. Higano

This research was presented at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), a gathering of over 30,000 oncology professionals in Chicago.

Celestia S. Higano, professor, Medical Oncology Division, University of Washington School of Medicine, discusses an analysis looking at sexual health and pelvic floor physiotherapy services for patients with prostate cancer. This research was presented at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), a gathering of over 30,000 oncology professionals in Chicago.

Related Videos
Adolescent and Young Adult Cancer Awareness Week sheds light on the financial hardships young cancer survivors face, including debt and limited assistance.
CURE spoke with Dr. William C. Huang about what kind of team may be required to treat a patient with metastatic kidney cancer.
Image of woman.
Image of woman.
Image of woman.
Image of man wearing baseball cap backwards.
Image of smiling doctor.
Registered nurse Patricia Jakel emphasizes the importance of educating patients on evolving breast cancer research and the need for routine screenings.
Dr. Debu Tripathy highlights the importance of staying informed on breast cancer advancements and how this empowers patients to make informed decisions.
Image od grey haired Doctor.
Related Content
FDA sign.
April 1st 2025

Dive Into March 2025 FDA Approvals Across Cancer Subtypes

Ryan Scott
Here is a roundup of March 2025 U.S. FDA approvals across cancer subtypes, including prostate, bladder and gastrointestinal cancers.
Image of CURE's Cancer Horizons podcast logo: a white microphone with yellow noise lines. Highlights from the 2024 ASCO gastrointestinal and genitourinary cancer conferences.
January 30th 2024

Highlights from the Gastrointestinal and Genitourinary Cancer Conferences

Alex Biese Brielle Benyon
Here are some of the top stories from the recent Gastrointestinal Cancers Symposium as well as the Genitourinary Cancers Symposium.
"FDA" text.
March 28th 2025

FDA Expands Pluvicto Indication in Prostate Cancer Subset

Spencer Feldman
FDA expands Pluvicto indication to adults with PSMA+ metastatic castration-resistant prostate cancer previously treated with androgen receptor inhibitors.
CURE Cancer Horizons podcast logo
January 29th 2024

Prostate Cancer Headlines, CAR-T Warnings and Laughter Therapy

Alex Biese Brielle Benyon
CURE® editors discuss last week’s biggest cancer headlines, from Dexter Scott King’s death to the potential of laughter therapy to boost quality of life.
Illustartion of prostate.
March 21st 2025

First Patent Dosed With Pocenbrodib in Trial for Metastatic Prostate Cancer

Spencer Feldman
First patient dosed in phase 1b/2a trial for castration-resistant metastatic prostate cancer, evaluating pocenbrodib alone and with other drug combinations.
The FDA has approved the use of Gozellix, a PSMA-PET imaging agent, to help detect prostate cancer using gallium-68 gozetotide in PSMA-PET scans.
March 21st 2025

FDA Approves Gozellix for Advanced PSMA-PET Imaging in Prostate Cancer

Ryan Scott
The FDA has approved the use of Gozellix, a PSMA-PET imaging agent, to help detect prostate cancer using gallium-68 gozetotide in PSMA-PET scans.